Return to content in this issue

 

Concomitant Efficacy of Dupilumab for severe atopic dermatitis and comorbid asthma in real-life conditions

Pose K1, Laorden D2, Hernández N3, Villamañán E4, Quirce S1,5,6, Domínguez-Ortega J1,5,6

1Department of Allergy, La Paz University Hospital, Madrid, Spain
2Department of Pulmonology, La Paz University Hospital, Madrid, Spain
3Department of Dermatology, La Paz University Hospital, Madrid, Spain
4Department of Hospital Pharmacy, La Paz University Hospital, Madrid, Spain
5La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
6CIBER of Respiratory Diseases (CIBERES), Madrid, Spain

J Investig Allergol Clin Immunol 2023; Vol. 33(2)
doi: 10.18176/jiaci.0837

Key words: Dupilumab, Asthma, Severe atopic dermatitis, Type 2 inflammatory diseases, IL-13